# Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19

> **NCT04661527** · PHASE2 · UNKNOWN · sponsor: **Clinica Universidad de Navarra, Universidad de Navarra** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19 Drug Treatment

## Interventions

- **DRUG:** Sarilumab

## Key facts

- **NCT ID:** NCT04661527
- **Lead sponsor:** Clinica Universidad de Navarra, Universidad de Navarra
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-22
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-12-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04661527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04661527, "Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04661527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*